Teva Pharma (TEVA) Reports In-Line Q1 EPS on Light Revs
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) reported Q1 EPS of $1.04, in-line with the analyst estimate of $1.04. Revenue for the quarter came in at $4.08 billion versus the consensus estimate of $4.25 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva shares Phase 3 data on once-monthly schizophrenia injection
- Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
